Mobile Navigation

Subscribe for the Newsletter

Company Info

Failed to load

Coriolis Pharma

Coriolis Pharma

CDMO / Preclinical CRO

Overview

Coriolis Pharma is a globally operating and science driven contract research and development organization (CRDO). We support drug product development of biopharmaceuticals, including gene and cell therapies and vaccines, from early development to commercialization. Our focus lies on formulation development, lyophilization technologies and analytics (GMP and non-GMP) for a wide range of products.

As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients.

We offer a large selection of services for all types of biopharmaceuticals, including proteins, peptides, peptides, nucleic acids, gene- and cell therapy products, vaccines and virus(-like) particles up to biosafety level S2.

Failed to load

Coriolis Pharma
Contributions
13 Contributions1 / 1

Failed to load

From Preclinical to Commercialization: A CRDO Approach to Accelerating Biologic Development
CRDO

From Preclinical to Commercialization: A CRDO Approach to Accelerating Biologic Development

Matthias Lucke, Ph.D.; Ivonne Stelzl, Ph.D.

Coriolis Pharma

PAO-08-25-CL-02Aug 04, 2025

Failed to load

From Prefilled Syringes to On-body Devices – How Optimized Biologics Formulations Improve Patient Adherence
Delivery Devices

From Prefilled Syringes to On-body Devices – How Optimized Biologics Formulations Improve Patient Adherence

Eva Keilhauer, Ph.D.; Andreas Stelzl, Ph.D.

Coriolis Pharma

PAO-06-25-CL-07Jul 08, 2025

Failed to load

The Importance of a Robust Formulation for Long-Term Drug Development Success
Formulation

The Importance of a Robust Formulation for Long-Term Drug Development Success

Michaela Breitsamer, Dr. rer. nat.

Coriolis Pharma

PAO-06-25-CL-04Jun 30, 2025

Failed to load

Leveraging Advanced GMP Release and Stability Testing Methods to Accelerate New Drug Development
Analytical

Leveraging Advanced GMP Release and Stability Testing Methods to Accelerate New Drug Development

Carsten Kroeger, Dr. rer. nat.; Gerhard Sax, Dr. rer. nat.

Coriolis Pharma

PAO-04-25-CL-03Apr 15, 2025

Failed to load

Advancing Subvisible Particle Characterization with Artificial Intelligence
Particle Analysis

Advancing Subvisible Particle Characterization with Artificial Intelligence

Daniel Weinbuch, Ph.D.

Coriolis Pharma

PAO-03-25-CL-02Mar 11, 2025

Failed to load

Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions
Lyophilization

Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions

Brecht Vanbillemont, Dr.; Lisa Besslich, Dr. Rer. Nat.

Coriolis Pharma

PAO-02-25-CL-12Feb 18, 2025

Failed to load

Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Developability

Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments

Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.

Coriolis Pharma

PAO-01-25-CL-12Jan 27, 2025

Failed to load

Leveraging Formulation Development Experience for Effective Particle Identification
Particle ID

Leveraging Formulation Development Experience for Effective Particle Identification

Jörg Müller, Ph.D.

Coriolis Pharma

PAO-10-24-CL-10Nov 18, 2024

Failed to load

Development Strategies for Overcoming Commercialization Challenges
Commercialization

Development Strategies for Overcoming Commercialization Challenges

Matthias Lucke, Ph.D.

Coriolis Pharma

PAO-09-24-CL-10Sep 17, 2024

Failed to load

IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"
IND Enablement

IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"

Johannes Clemens

Coriolis Pharma

PAO-08-24-CL-07Aug 16, 2024

Failed to load

Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Developability

Streamlining the Path to Approval with Developability and Pre-Formulation Platforms

Andrea Hawe

Coriolis Pharma

PAO-07-24-CL-11Aug 01, 2024

Failed to load

Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
CRDO

Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development

Silvia Steyrer-Gruber

Coriolis Pharma

PAO-07-24-CL-05Jul 16, 2024

Failed to load

Coriolis Pharma
Monoclonal Antibodies

Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies

Coriolis Pharma

PR-05-24-NI-02Jun 18, 2024
1 / 1